In addition, it is reasonable to assume that increased serum levels of PAPP-A2 in lung cancer patients may correlate with augmented IGF signaling in tumor cells, and thus, PAPP-A2 may also possess potential as a biomarker for IGF-I targeted therapy. The gene discussed is PAPPA2; the disease is neoplasm.